Trial Profile
The effectiveness of switching to Tiotropium / Olodaterol combination in patients with COPD
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jun 2022
Price :
$35
*
At a glance
- Drugs Olodaterol/tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 06 Jun 2022 Status changed from active, no longer recruiting to completed.
- 21 Jun 2018 New trial record